Hefei Chuandi Pharmaceutical Technology Co., Ltd.

To further evaluate the safety and efficacy of compound roxithromycin tablets in the treatment of mild and moderate acute lower respiratory tract bacterial infections with viscous sputum using roxithromycin as a control

To evaluate the efficacy and safety of compound roxithromycin dispersible tablets in the treatment of lower respiratory tract infection with thick sputum

Examine whether the degree and rate of absorption in the body of the two main drugs in the test preparation (roxithromycin and ambroxol hydrochloride) are significantly different from those of the two main drugs alone, and examine whether the combined use of roxithromycin and ambroxol hydrochloride There are drug interactions. Examine the steady-state average plasma concentration (Cav) of compound roxithromycin dispersible tablets after multiple administrations, the drug trough and peak concentrations when reaching steady state, and the fluctuation coefficient (DF) of steady-state plasma concentration. After multiple administrations, Whether the drug has drug accumulation effect.